Capricor Therapeutics Inc (NASDAQ:CAPR) Receives Consensus Rating of “Buy” from Analysts

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) have been given a consensus rating of “Buy” by the six ratings firms that are covering the company, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokers that have covered the stock in the last year is $34.50.

A number of equities analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $77.00 price objective on shares of Capricor Therapeutics in a research report on Thursday, January 2nd. Piper Sandler started coverage on Capricor Therapeutics in a research report on Monday, October 21st. They issued an “overweight” rating and a $35.00 target price on the stock. Finally, Cantor Fitzgerald lifted their target price on Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th.

Institutional Investors Weigh In On Capricor Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of CAPR. Point72 Asset Management L.P. purchased a new stake in shares of Capricor Therapeutics in the 3rd quarter valued at $3,806,000. PFM Health Sciences LP acquired a new position in Capricor Therapeutics during the 3rd quarter worth $2,324,000. State Street Corp grew its stake in Capricor Therapeutics by 27.8% during the 3rd quarter. State Street Corp now owns 512,313 shares of the biotechnology company’s stock worth $7,792,000 after purchasing an additional 111,291 shares in the last quarter. Marshall Wace LLP purchased a new stake in Capricor Therapeutics during the 2nd quarter valued at approximately $426,000. Finally, Renaissance Technologies LLC grew its holdings in Capricor Therapeutics by 158.7% during the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock valued at $656,000 after buying an additional 84,350 shares during the last quarter. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Stock Performance

Shares of Capricor Therapeutics stock opened at $14.80 on Monday. Capricor Therapeutics has a one year low of $3.52 and a one year high of $23.40. The company has a market cap of $672.96 million, a price-to-earnings ratio of -13.96 and a beta of 4.08. The business’s 50 day moving average price is $15.06 and its 200 day moving average price is $11.94.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.